David Statman

In this video, Catherine Lai, MD, MPH discusses the results of a study presented at ASH Annual Meeting that examined the use of FLT-3 inhibitors in leukemia patients with an FLT-3 mutation.Lai, an assistant professor of clinical medicine at the University of Pennsylvania, highlighted the study, which looked at patients receiving treatment with the FLT-3 inhibitors midostaurin (Rydapt, Novartis)

In this video, Catherine Lai, MD, MPH discusses the results of a study presented at ASH Annual Meeting that examined time to treatment initiation in patients with acute myeloid leukemia.Lai, an assistant professor of clinical medicine at the University of Pennsylvania, highlighted the study, which looked at patients receiving treatment with azacitidine (Onureg, Bristol Myers Squibb) and

In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined the use of hydroxyurea in patients with hemoglobin SC disease.Mistry, an assistant professor at University of Pennsylvania, highlighted the phase 2 PIVOT study — a Ghanaian trial that treated patients with a medication generally used for sickle cell disease with hemoglobin SS

In this video, Daniel DeAngelo, MD, PhD, discusses a study presented at ASH Annual Meeting that examined the KOMET-007 study into the use of menin inhibitors in patients with acute myeloid leukemia.DeAngelo, chief of the division of leukemia at Dana-Farber Cancer Institute, highlighted the study, which probed the menin inhibitor ziftomenib [Kura Oncology] combined with intensive therapy.

In this video, Daniel DeAngelo, MD, PhD, discusses the results of a study presented at ASH Annual Meeting 2024 that examined the use of menin inhibitors in patients with leukemia.DeAngelo, chief of the division of leukemia at Dana-Farber Cancer Institute, highlighted a phase 2 study of revumenib (Revuforj, Syndax Pharmaceuticals) in patients with relapsed or refractory KMT2A acute leukemia.

In this video, Amy Dickey, MD, MSc, discusses a study presented at ASH Annual Meeting that examined the use of an ABCG2 inhibitor in patients with erythropoetic protoporphyria.Dickey, an assistant professor at Massachusetts General Hospital, highlighted the study, which presented results in mice that she characterized as promising for its eventual use in humans.

In this video, Amy Dickey, MD, MSc, discusses the results of a study she presented at ASH Annual Meeting, which examined the use of bitopertin in patients with erythropoetic protoporphyria.Dickey, an assistant professor at Massachusetts General Hospital, highlighted the study, which specifically targeted the form of porphyria that manifests in painful light sensitivity in its patients.

In this video, Amy Dickey, MD, MSc, discusses a study presented at ASH Annual Meeting that examined treatment of erythropoetic protoporphyria and X-linked protoporphyria.Dickey, an assistant professor at Massachusetts General Hospital, highlighted the study, which specifically looked into disrupting the iron-responsive element that leads to heme synthesis and worsening disease.

In this video, Amy Dickey, MD, MSc, discusses a study presented at ASH Annual Meetingthat examined treatment of Diamond-Blackfan anemia with bitopertin.Dickey, an assistant professor at Massachusetts General Hospital, highlighted the study, which specifically looked into treatment of the rare type of anemia with a medication often used for erythropoetic protoporphyria.

In this video, Noah Merin, MD, PhD, discusses the results of a Chinese study into the use of venetoclax in the treatment of acute myeloid leukemia and non-Hodgkin lymphoma, presented at ESMO Congress.Merin, director of the leukemia program at Cedars-Sinai Medical Center, highlighted the study, which was a dose escalation expansion study of a class of drug that AML has already displayed